Abstract
Hepatocyte growth factor (HGF) plays a plethora of roles in the progression of many invasive and metastatic cancers. The interaction between tumour cells and their surrounding stromal environment remains a crucial factor governing tumour invasion and metastasis. HGF is primarily synthesised by stromal fibroblasts as an inactive precursor known as pro-HGF. A number of proteases have demonstrated the ability to convert pro-HGF into the biologically active form of HGF, although the two main factors responsible are HGF activator (HGFA) and matriptase. The HGF activation inhibitors (HAI-1 and HAI-2) are two novel Kunitz-type serine protease inhibitors that regulate HGFA and matriptase activity to govern the influence of HGF within the body. Deregulation of HAI expression can lead to shift in the HGF activation/inhibition balance ratio in favour of enhanced HGF production. Therefore, these HGF activation inhibitors may have a direct bearing on cancer invasion and metastasis. This review examines the accumulating evidence on the emerging role and therapeutic potential of HAI-1 and HAI-2 in cancer.
Keywords: Hepatocyte growth factor, matriptase, HGF activator, HGF inhibitor, HAI-1, HAI-2, prognosis
Anti-Cancer Agents in Medicinal Chemistry
Title: Hepatocyte Growth Factor Activation Inhibitors – Therapeutic Potential in Cancer
Volume: 10 Issue: 1
Author(s): Christian Parr, Andrew J. Sanders and Wen G. Jiang
Affiliation:
Keywords: Hepatocyte growth factor, matriptase, HGF activator, HGF inhibitor, HAI-1, HAI-2, prognosis
Abstract: Hepatocyte growth factor (HGF) plays a plethora of roles in the progression of many invasive and metastatic cancers. The interaction between tumour cells and their surrounding stromal environment remains a crucial factor governing tumour invasion and metastasis. HGF is primarily synthesised by stromal fibroblasts as an inactive precursor known as pro-HGF. A number of proteases have demonstrated the ability to convert pro-HGF into the biologically active form of HGF, although the two main factors responsible are HGF activator (HGFA) and matriptase. The HGF activation inhibitors (HAI-1 and HAI-2) are two novel Kunitz-type serine protease inhibitors that regulate HGFA and matriptase activity to govern the influence of HGF within the body. Deregulation of HAI expression can lead to shift in the HGF activation/inhibition balance ratio in favour of enhanced HGF production. Therefore, these HGF activation inhibitors may have a direct bearing on cancer invasion and metastasis. This review examines the accumulating evidence on the emerging role and therapeutic potential of HAI-1 and HAI-2 in cancer.
Export Options
About this article
Cite this article as:
Parr Christian, Sanders J. Andrew and Jiang G. Wen, Hepatocyte Growth Factor Activation Inhibitors – Therapeutic Potential in Cancer, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (1) . https://dx.doi.org/10.2174/1871520611009010047
DOI https://dx.doi.org/10.2174/1871520611009010047 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Allergic Asthma: A Summary from Genetic Basis, Mouse Studies, to Diagnosis and Treatment
Current Pharmaceutical Design Recent Progress in the Development of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Prostate Cancer with Variants in CYP17 and UGT2B17 Genes: A Meta-Analysis
Protein & Peptide Letters Supplements, Diets and Other Complementary and Alternative Interventions in Adolescent Mental Health
Adolescent Psychiatry Ginkgo biloba as an Alternative Medicine in the Treatment of Anxiety in Dementia and other Psychiatric Disorders
Current Drug Metabolism 4-Aryl-4H-Chromene-3-Carbonitrile Derivatives: Evaluation of Src Kinase Inhibitory and Anticancer Activities
Medicinal Chemistry From Amino Acids to Proteins as Targets for Metal-based Drugs
Current Drug Metabolism Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions
Current Cancer Drug Targets Anti-inflammatory, Antioxidant and Antiproliferative Activities from Trichilia silvatica (C.DC)
Current Pharmaceutical Biotechnology Naturally Plant-Derived Compounds: Role in Bone Anabolism
Current Molecular Pharmacology Advances and Perspectives in Cell-Specific Aptamers
Current Pharmaceutical Design Hedgehog Signaling in the Normal and Neoplastic Mammary Gland
Current Drug Targets Editorial (Thematic Issue: Breast Cancer Clinical Trials – The Era of the Surrogates)
Reviews on Recent Clinical Trials Evaluation of Cytotoxic Mechanisms of Clinacanthus Nutans Extracts in Cancer Cells
The Natural Products Journal Nitric Oxide and Pancreatic Cancer Pathogenesis, Prevention, and Treatment
Current Pharmaceutical Design Tomato Lycopene and Inflammatory Cascade: Basic Interactions and Clinical Implications
Current Medicinal Chemistry Histone Deacetylase Inhibitors in Tumor Immunotherapy
Current Medicinal Chemistry Challenges of Cancer Drug Design A Drug Metabolism Perspective
Current Cancer Drug Targets Green Tea Catechins: Proposed Mechanisms of Action in Breast Cancer Focusing on the Interplay Between Survival and Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Improving the Classification of Nuclear Receptors with Feature Selection
Protein & Peptide Letters